Login

|

Register

Britain’s Ashwagandha Safety Review Is Still Not Closed

Britain's safety review of ashwagandha remains open, so supplement brands still need their own extract and dose evidence.

The UK Committee on Toxicity discussed a third draft statement on ashwagandha on 8 September 2026, so the formal risk assessment remains open and no UK or EU conclusion has been published. A separate 90-day study of one branded extract in 62 adults reported no adverse signals, but it was supplier-funded.